AbbVie (NYSE: ABBV) announces that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie. Nimble’s lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble’s peptide synthesis, screening, and optimization platform uses proprietary technology to help drive rapid discovery and optimization of oral peptide candidates for a range of targets.
Read the full article: AbbVie Completes Acquisition of Nimble Therapeutics //
Source: https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-nimble-therapeutics-302358709.html